Aquestive Therapeutics, Inc. AQST
Set alert
At close
Pre-market · Nov 3, 4:00 AM ET
- YTD
- -41.64%
- 1 year
- -41.91%
- Open
- 3.92
- Prev close
- 3.89
- Mkt cap
- 473.18M
- Vol
- 2.63M
- Avg vol
- 2.74M
- EPS
- -0.66
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.64
- High
- 3.96
- Forward P/E
- -5.87
- Beta
- 2.82
- Short ratio
- 6.37
- Inst. own
- 55.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 4.68
- 200-d avg
- 4.02
- 1y target
- 10.83
5D chart
Signals (56)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 13 hours ago |
| RSI: Overbought | Nov 2, 3:10 PM | 13 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 14 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 14 hours ago |
| MACD: Buy Signal | Nov 2, 2:40 PM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 2:25 PM | 14 hours ago |
| SMA: Bearish | Nov 2, 1:40 PM | 15 hours ago |
| SMA: Bearish | Nov 2, 12:50 PM | 16 hours ago |
| SMA: Bullish | Nov 2, 12:25 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 12:15 PM | 16 hours ago |
| SMA: Bullish | Nov 2, 12:10 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 12:10 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 12:05 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 12:00 PM | 16 hours ago |
| RSI: Oversold | Nov 2, 11:40 AM | 17 hours ago |
| RSI: Oversold | Nov 2, 10:35 AM | 18 hours ago |
| MACD: Sell Signal | Nov 2, 10:05 AM | 18 hours ago |
| SMA: Bearish | Nov 2, 9:50 AM | 19 hours ago |
| SMA: Bearish | Nov 2, 9:50 AM | 19 hours ago |
| SMA: Bullish | Nov 2, 9:45 AM | 19 hours ago |
Newest 20 of 56.
News
6 days ago globenewswire.com
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful…
-
2 weeks ago benzinga.com
FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with…
2 weeks ago benzinga.com
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.
-
2 weeks ago benzinga.com
Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually…